Spain
Medical device market intelligence for Spain. Regulatory changes, competitor moves, and procurement trends.
Recent signals
The Nit-Occlud® Lê VSD Spiral Coil System is evaluated for safety and effectiveness in VSD treatment across multiple countries.
The BIOTRABIS study aims to validate a POC device for diagnosing mTBI using the H-FABP biomarker in emergency settings.
PAUL HARTMANN AG's registration number 3003096716 is for a product listed under code EYQ.
Novaf Andalucia 2007, S.L. has FDA registration for product code KNO, listing one medical device.
A completed study measured patient satisfaction with a Bluetooth-connected adrenaline autoinjector for anaphylaxis.
The ABLE exoskeleton study assessed design changes for safety and usability in spinal cord injury patients.
The ABLE Exoskeleton device's safety and performance were validated in a study for acquired brain injury patients.
The study evaluates the safety and efficacy of GORE® devices for treating aorto-iliac aneurysms affecting bifurcations.
The clinical trial assessed the INTORUS device's efficacy in reducing exam anxiety among university students.
Cleverscope is a new device transforming laryngoscopes into videolaryngoscopes, undergoing safety and efficacy evaluation.
A new fixative device for intravenous therapies is currently in recruiting phase to reduce complications.
Philips Ultrasound LLC registered the Extended Compact Cart as a Class I medical device in EUDAMED.
The MOWOOT device has completed a study assessing its safety and efficacy for treating chronic constipation.
A mobile app is being validated for detecting pulmonary function disorders using exhaled air sounds in Spain.
The UNI-VEC device is being tested for safety and effectiveness in rectal tumor resection in a clinical trial.
The Armeo Spring device was analyzed for its effectiveness in rehabilitation for spinal cord injury patients.
The GOCCLES® device aims to enhance early diagnosis of oral potentially malignant disorders and oral cancer.
The ABLE Exoskeleton study confirms its feasibility for spinal cord injury patients in home and community settings.
The ABLE Exoskeleton device's safety and performance were validated in a clinical study for multiple sclerosis patients.
BraiN20® shows high predictive accuracy for recovery in AIS patients undergoing EVT, validated in Spain.